#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1.
1-1	0-2	1.	_	_	_	_

#Text=Introduction
2-1	3-15	Introduction	abstract	new	_	_

#Text=The liver is the central organ of lipid metabolism .
3-1	16-19	The	object[2]	new[2]	coref	3-4[3_2]
3-2	20-25	liver	object[2]	new[2]	_	_
3-3	26-28	is	_	_	_	_
3-4	29-32	the	object[3]	giv[3]	coref	4-7[9_3]
3-5	33-40	central	object[3]	giv[3]	_	_
3-6	41-46	organ	object[3]	giv[3]	_	_
3-7	47-49	of	object[3]	giv[3]	_	_
3-8	50-55	lipid	object[3]|object|abstract[5]	giv[3]|new|new[5]	coref|coref	12-7|19-7[128_5]
3-9	56-66	metabolism	object[3]|abstract[5]	giv[3]|new[5]	_	_
3-10	67-68	.	_	_	_	_

#Text=Dietary fatty acids are transported to the liver and oxidized to produce as much energy as the hepatocyte needs .
4-1	69-76	Dietary	person|substance[8]	new|new[8]	coref	5-1[12_8]
4-2	77-82	fatty	abstract|substance[8]	new|new[8]	coref	5-3
4-3	83-88	acids	substance[8]	new[8]	_	_
4-4	89-92	are	_	_	_	_
4-5	93-104	transported	_	_	_	_
4-6	105-107	to	_	_	_	_
4-7	108-111	the	object[9]	giv[9]	coref	6-14[0_9]
4-8	112-117	liver	object[9]	giv[9]	_	_
4-9	118-121	and	_	_	_	_
4-10	122-130	oxidized	_	_	_	_
4-11	131-133	to	_	_	_	_
4-12	134-141	produce	_	_	_	_
4-13	142-144	as	_	_	_	_
4-14	145-149	much	_	_	_	_
4-15	150-156	energy	_	_	_	_
4-16	157-159	as	_	_	_	_
4-17	160-163	the	substance[10]	new[10]	coref	5-15[15_10]
4-18	164-174	hepatocyte	substance[10]	new[10]	_	_
4-19	175-180	needs	_	_	_	_
4-20	181-182	.	_	_	_	_

#Text=The excess fatty acids are converted to triglycerides ( TG ) and stored in the hepatocyte .
5-1	183-186	The	substance[12]	giv[12]	_	_
5-2	187-193	excess	substance[12]	giv[12]	_	_
5-3	194-199	fatty	abstract|substance[12]	giv|giv[12]	coref	7-18
5-4	200-205	acids	substance[12]	giv[12]	_	_
5-5	206-209	are	_	_	_	_
5-6	210-219	converted	_	_	_	_
5-7	220-222	to	_	_	_	_
5-8	223-236	triglycerides	substance	new	appos	5-10
5-9	237-238	(	_	_	_	_
5-10	239-241	TG	substance	giv	coref	6-5
5-11	242-243	)	_	_	_	_
5-12	244-247	and	_	_	_	_
5-13	248-254	stored	_	_	_	_
5-14	255-257	in	_	_	_	_
5-15	258-261	the	place[15]	giv[15]	_	_
5-16	262-272	hepatocyte	place[15]	giv[15]	_	_
5-17	273-274	.	_	_	_	_

#Text=When the amount of TG accounts for more than 5 % of the liver weight , the organ function is impaired , and this condition is known as fatty liver disease .
6-1	275-279	When	_	_	_	_
6-2	280-283	the	quantity[16]	new[16]	_	_
6-3	284-290	amount	quantity[16]	new[16]	_	_
6-4	291-293	of	quantity[16]	new[16]	_	_
6-5	294-296	TG	quantity[16]|substance	new[16]|giv	_	_
6-6	297-305	accounts	_	_	_	_
6-7	306-309	for	_	_	_	_
6-8	310-314	more	_	_	_	_
6-9	315-319	than	_	_	_	_
6-10	320-321	5	quantity[18]	new[18]	_	_
6-11	322-323	%	quantity[18]	new[18]	_	_
6-12	324-326	of	quantity[18]	new[18]	_	_
6-13	327-330	the	quantity[18]|abstract[20]	new[18]|new[20]	_	_
6-14	331-336	liver	quantity[18]|object|abstract[20]	new[18]|giv|new[20]	coref	6-18
6-15	337-343	weight	quantity[18]|abstract[20]	new[18]|new[20]	_	_
6-16	344-345	,	_	_	_	_
6-17	346-349	the	abstract[22]	new[22]	_	_
6-18	350-355	organ	object|abstract[22]	giv|new[22]	coref	6-30
6-19	356-364	function	abstract[22]	new[22]	_	_
6-20	365-367	is	_	_	_	_
6-21	368-376	impaired	_	_	_	_
6-22	377-378	,	_	_	_	_
6-23	379-382	and	_	_	_	_
6-24	383-387	this	abstract[23]	new[23]	_	_
6-25	388-397	condition	abstract[23]	new[23]	_	_
6-26	398-400	is	_	_	_	_
6-27	401-406	known	_	_	_	_
6-28	407-409	as	_	_	_	_
6-29	410-415	fatty	abstract[25]	new[25]	coref	11-1[56_25]
6-30	416-421	liver	object|abstract[25]	giv|new[25]	coref	7-12[29_0]
6-31	422-429	disease	abstract[25]	new[25]	_	_
6-32	430-431	.	_	_	_	_

#Text=Chronic alcohol intake has long been considered the major cause of alcoholic fatty liver , while non-alcoholic fatty liver has been shown to be unrelated to alcohol intake .
7-1	432-439	Chronic	event[27]	new[27]	coref	7-27[33_27]
7-2	440-447	alcohol	substance|event[27]	new|new[27]	coref	7-27
7-3	448-454	intake	event[27]	new[27]	_	_
7-4	455-458	has	_	_	_	_
7-5	459-463	long	_	_	_	_
7-6	464-468	been	_	_	_	_
7-7	469-479	considered	_	_	_	_
7-8	480-483	the	abstract[28]	new[28]	_	_
7-9	484-489	major	abstract[28]	new[28]	_	_
7-10	490-495	cause	abstract[28]	new[28]	_	_
7-11	496-498	of	abstract[28]	new[28]	_	_
7-12	499-508	alcoholic	abstract[28]|object[29]	new[28]|giv[29]	coref	7-17[31_29]
7-13	509-514	fatty	abstract[28]|object[29]	new[28]|giv[29]	_	_
7-14	515-520	liver	abstract[28]|object[29]	new[28]|giv[29]	_	_
7-15	521-522	,	_	_	_	_
7-16	523-528	while	_	_	_	_
7-17	529-542	non-alcoholic	object[31]	giv[31]	coref	8-4[35_31]
7-18	543-548	fatty	animal|object[31]	giv|giv[31]	_	_
7-19	549-554	liver	object[31]	giv[31]	_	_
7-20	555-558	has	_	_	_	_
7-21	559-563	been	_	_	_	_
7-22	564-569	shown	_	_	_	_
7-23	570-572	to	_	_	_	_
7-24	573-575	be	_	_	_	_
7-25	576-585	unrelated	_	_	_	_
7-26	586-588	to	_	_	_	_
7-27	589-596	alcohol	substance|event[33]	giv|giv[33]	coref	8-13[39_33]
7-28	597-603	intake	event[33]	giv[33]	_	_
7-29	604-605	.	_	_	_	_

#Text=The causes of non-alcoholic fatty liver are lifestyle habits , which include excessive dietary intake and lack of energy consumption .
8-1	606-609	The	abstract[34]	new[34]	coref	8-8[37_34]
8-2	610-616	causes	abstract[34]	new[34]	_	_
8-3	617-619	of	abstract[34]	new[34]	_	_
8-4	620-633	non-alcoholic	abstract[34]|object[35]	new[34]|giv[35]	coref	10-17[54_35]
8-5	634-639	fatty	abstract[34]|object[35]	new[34]|giv[35]	_	_
8-6	640-645	liver	abstract[34]|object[35]	new[34]|giv[35]	_	_
8-7	646-649	are	_	_	_	_
8-8	650-659	lifestyle	abstract|abstract[37]	new|giv[37]	coref	9-8
8-9	660-666	habits	abstract[37]	giv[37]	_	_
8-10	667-668	,	_	_	_	_
8-11	669-674	which	_	_	_	_
8-12	675-682	include	_	_	_	_
8-13	683-692	excessive	event[39]	giv[39]	_	_
8-14	693-700	dietary	abstract|event[39]	new|giv[39]	_	_
8-15	701-707	intake	event[39]	giv[39]	_	_
8-16	708-711	and	_	_	_	_
8-17	712-716	lack	abstract[40]	new[40]	_	_
8-18	717-719	of	abstract[40]	new[40]	_	_
8-19	720-726	energy	abstract[40]|abstract[41]	new[40]|new[41]	ana	9-3[0_41]
8-20	727-738	consumption	abstract[40]|abstract[41]	new[40]|new[41]	_	_
8-21	739-740	.	_	_	_	_

#Text=Therefore , it is often accompanied by lifestyle diseases such as obesity , diabetes , and metabolic syndrome .
9-1	741-750	Therefore	_	_	_	_
9-2	751-752	,	_	_	_	_
9-3	753-755	it	abstract	giv	_	_
9-4	756-758	is	_	_	_	_
9-5	759-764	often	_	_	_	_
9-6	765-776	accompanied	_	_	_	_
9-7	777-779	by	_	_	_	_
9-8	780-789	lifestyle	abstract|abstract[44]	giv|new[44]	coref	10-10[52_44]
9-9	790-798	diseases	abstract[44]	new[44]	_	_
9-10	799-803	such	abstract[44]	new[44]	_	_
9-11	804-806	as	abstract[44]	new[44]	_	_
9-12	807-814	obesity	abstract[44]|abstract|abstract[46]	new[44]|new|new[46]	coref|coref	14-6|14-6[71_46]
9-13	815-816	,	abstract[44]|abstract[46]	new[44]|new[46]	_	_
9-14	817-825	diabetes	abstract[44]|abstract[46]|abstract	new[44]|new[46]|new	coref	14-8
9-15	826-827	,	abstract[44]|abstract[46]	new[44]|new[46]	_	_
9-16	828-831	and	abstract[44]|abstract[46]	new[44]|new[46]	_	_
9-17	832-841	metabolic	abstract[44]|abstract[46]|person|abstract[49]	new[44]|new[46]|new|new[49]	_	_
9-18	842-850	syndrome	abstract[44]|abstract[46]|abstract[49]	new[44]|new[46]|new[49]	_	_
9-19	851-852	.	_	_	_	_

#Text=In recent times , with the growing incidence of these diseases , the attention paid to non-alcoholic fatty liver is gradually increasing .
10-1	853-855	In	_	_	_	_
10-2	856-862	recent	time[50]	new[50]	_	_
10-3	863-868	times	time[50]	new[50]	_	_
10-4	869-870	,	_	_	_	_
10-5	871-875	with	_	_	_	_
10-6	876-879	the	abstract[51]	new[51]	_	_
10-7	880-887	growing	abstract[51]	new[51]	_	_
10-8	888-897	incidence	abstract[51]	new[51]	_	_
10-9	898-900	of	abstract[51]	new[51]	_	_
10-10	901-906	these	abstract[51]|abstract[52]	new[51]|giv[52]	coref	26-23[188_52]
10-11	907-915	diseases	abstract[51]|abstract[52]	new[51]|giv[52]	_	_
10-12	916-917	,	_	_	_	_
10-13	918-921	the	abstract[53]	new[53]	_	_
10-14	922-931	attention	abstract[53]	new[53]	_	_
10-15	932-936	paid	_	_	_	_
10-16	937-939	to	_	_	_	_
10-17	940-953	non-alcoholic	object[54]	giv[54]	coref	11-3[0_54]
10-18	954-959	fatty	object[54]	giv[54]	_	_
10-19	960-965	liver	object[54]	giv[54]	_	_
10-20	966-968	is	_	_	_	_
10-21	969-978	gradually	_	_	_	_
10-22	979-989	increasing	_	_	_	_
10-23	990-991	.	_	_	_	_

#Text=Non-alcoholic fatty liver disease ( NAFLD ) shows various stages .
11-1	992-1005	Non-alcoholic	abstract[56]	giv[56]	appos	11-6[0_56]
11-2	1006-1011	fatty	abstract[56]	giv[56]	_	_
11-3	1012-1017	liver	object|abstract[56]	giv|giv[56]	coref	15-11[83_0]
11-4	1018-1025	disease	abstract[56]	giv[56]	_	_
11-5	1026-1027	(	_	_	_	_
11-6	1028-1033	NAFLD	abstract	giv	coref	14-18
11-7	1034-1035	)	_	_	_	_
11-8	1036-1041	shows	_	_	_	_
11-9	1042-1049	various	abstract[58]	new[58]	_	_
11-10	1050-1056	stages	abstract[58]	new[58]	_	_
11-11	1057-1058	.	_	_	_	_

#Text=Simple hepatic steatosis is characterized by lipid accumulation in hepatocytes .
12-1	1059-1065	Simple	abstract[60]	new[60]	_	_
12-2	1066-1073	hepatic	abstract|abstract[60]	new|new[60]	_	_
12-3	1074-1083	steatosis	abstract[60]	new[60]	_	_
12-4	1084-1086	is	_	_	_	_
12-5	1087-1100	characterized	_	_	_	_
12-6	1101-1103	by	_	_	_	_
12-7	1104-1109	lipid	abstract|abstract[62]	giv|new[62]	coref|coref	19-7|19-13[130_62]
12-8	1110-1122	accumulation	abstract[62]	new[62]	_	_
12-9	1123-1125	in	abstract[62]	new[62]	_	_
12-10	1126-1137	hepatocytes	abstract[62]|object	new[62]|new	coref	19-16
12-11	1138-1139	.	_	_	_	_

#Text=Non-alcoholic steatohepatitis ( NASH ) can be further developed into cirrhosis and hepatocellular carcinoma .
13-1	1140-1153	Non-alcoholic	abstract[64]	new[64]	_	_
13-2	1154-1169	steatohepatitis	abstract[64]	new[64]	_	_
13-3	1170-1171	(	_	_	_	_
13-4	1172-1176	NASH	substance	new	_	_
13-5	1177-1178	)	_	_	_	_
13-6	1179-1182	can	_	_	_	_
13-7	1183-1185	be	_	_	_	_
13-8	1186-1193	further	_	_	_	_
13-9	1194-1203	developed	_	_	_	_
13-10	1204-1208	into	_	_	_	_
13-11	1209-1218	cirrhosis	abstract	new	_	_
13-12	1219-1222	and	_	_	_	_
13-13	1223-1237	hepatocellular	abstract|abstract[68]	new|new[68]	_	_
13-14	1238-1247	carcinoma	abstract[68]	new[68]	_	_
13-15	1248-1249	.	_	_	_	_

#Text=Although many factors such as obesity , diabetes , and inflammation have been implicated in relation to NAFLD in humans , the underlying mechanism of the development and progression of NAFLD remains unclear .
14-1	1250-1258	Although	_	_	_	_
14-2	1259-1263	many	abstract[69]	new[69]	coref	15-14[86_69]
14-3	1264-1271	factors	abstract[69]	new[69]	_	_
14-4	1272-1276	such	abstract[69]	new[69]	_	_
14-5	1277-1279	as	abstract[69]	new[69]	_	_
14-6	1280-1287	obesity	abstract[69]|abstract|abstract[71]	new[69]|giv|giv[71]	_	_
14-7	1288-1289	,	abstract[69]|abstract[71]	new[69]|giv[71]	_	_
14-8	1290-1298	diabetes	abstract[69]|abstract[71]|abstract	new[69]|giv[71]|giv	_	_
14-9	1299-1300	,	abstract[69]|abstract[71]	new[69]|giv[71]	_	_
14-10	1301-1304	and	abstract[69]|abstract[71]	new[69]|giv[71]	_	_
14-11	1305-1317	inflammation	abstract[69]|abstract[71]|abstract	new[69]|giv[71]|new	_	_
14-12	1318-1322	have	_	_	_	_
14-13	1323-1327	been	_	_	_	_
14-14	1328-1338	implicated	_	_	_	_
14-15	1339-1341	in	_	_	_	_
14-16	1342-1350	relation	abstract[74]	new[74]	_	_
14-17	1351-1353	to	abstract[74]	new[74]	_	_
14-18	1354-1359	NAFLD	abstract[74]|abstract	new[74]|giv	coref	14-31
14-19	1360-1362	in	_	_	_	_
14-20	1363-1369	humans	person	new	_	_
14-21	1370-1371	,	_	_	_	_
14-22	1372-1375	the	abstract[77]	new[77]	_	_
14-23	1376-1386	underlying	abstract[77]	new[77]	_	_
14-24	1387-1396	mechanism	abstract[77]	new[77]	_	_
14-25	1397-1399	of	abstract[77]	new[77]	_	_
14-26	1400-1403	the	abstract[77]|event[78]	new[77]|new[78]	_	_
14-27	1404-1415	development	abstract[77]|event[78]	new[77]|new[78]	_	_
14-28	1416-1419	and	abstract[77]	new[77]	_	_
14-29	1420-1431	progression	abstract[77]|event[79]	new[77]|new[79]	_	_
14-30	1432-1434	of	abstract[77]|event[79]	new[77]|new[79]	_	_
14-31	1435-1440	NAFLD	abstract[77]|event[79]|abstract	new[77]|new[79]|giv	coref	16-27
14-32	1441-1448	remains	_	_	_	_
14-33	1449-1456	unclear	_	_	_	_
14-34	1457-1458	.	_	_	_	_

#Text=When free fatty acid ( FFA ) is overloaded in the body , FFA uptake factors such as cluster of differentiation 36 ( CD36 ) and fatty acid transport proteins ( FATPs ) are significantly up-regulated , and then excessive FFA is accepted into the liver , gradually accumulating .
15-1	1459-1463	When	_	_	_	_
15-2	1464-1468	free	substance[81]	new[81]	coref	15-28[0_81]
15-3	1469-1474	fatty	substance[81]	new[81]	_	_
15-4	1475-1479	acid	substance[81]	new[81]	_	_
15-5	1480-1481	(	_	_	_	_
15-6	1482-1485	FFA	abstract	new	coref	15-14
15-7	1486-1487	)	_	_	_	_
15-8	1488-1490	is	_	_	_	_
15-9	1491-1501	overloaded	_	_	_	_
15-10	1502-1504	in	_	_	_	_
15-11	1505-1508	the	object[83]	giv[83]	coref	15-45[95_83]
15-12	1509-1513	body	object[83]	giv[83]	_	_
15-13	1514-1515	,	_	_	_	_
15-14	1516-1519	FFA	abstract|abstract[86]	giv|giv[86]	coref|coref	15-40[94_0]|21-18[142_86]
15-15	1520-1526	uptake	abstract|abstract[86]	new|giv[86]	_	_
15-16	1527-1534	factors	abstract[86]	giv[86]	_	_
15-17	1535-1539	such	abstract[86]	giv[86]	_	_
15-18	1540-1542	as	abstract[86]	giv[86]	_	_
15-19	1543-1550	cluster	abstract[86]|abstract[87]	giv[86]|new[87]	_	_
15-20	1551-1553	of	abstract[86]|abstract[87]	giv[86]|new[87]	_	_
15-21	1554-1569	differentiation	abstract[86]|abstract[87]|abstract[88]	giv[86]|new[87]|new[88]	appos	15-24[0_88]
15-22	1570-1572	36	abstract[86]|abstract[87]|abstract[88]	giv[86]|new[87]|new[88]	_	_
15-23	1573-1574	(	abstract[86]	giv[86]	_	_
15-24	1575-1579	CD36	abstract[86]|abstract	giv[86]|giv	coref	17-12[108_0]
15-25	1580-1581	)	abstract[86]	giv[86]	_	_
15-26	1582-1585	and	abstract[86]	giv[86]	_	_
15-27	1586-1591	fatty	abstract[86]|substance[92]	giv[86]|new[92]	_	_
15-28	1592-1596	acid	abstract[86]|substance|substance[92]	giv[86]|giv|new[92]	coref	16-6[97_0]
15-29	1597-1606	transport	abstract[86]|abstract|substance[92]	giv[86]|new|new[92]	_	_
15-30	1607-1615	proteins	abstract[86]|substance[92]	giv[86]|new[92]	_	_
15-31	1616-1617	(	_	_	_	_
15-32	1618-1623	FATPs	object	new	_	_
15-33	1624-1625	)	_	_	_	_
15-34	1626-1629	are	_	_	_	_
15-35	1630-1643	significantly	_	_	_	_
15-36	1644-1656	up-regulated	_	_	_	_
15-37	1657-1658	,	_	_	_	_
15-38	1659-1662	and	_	_	_	_
15-39	1663-1667	then	_	_	_	_
15-40	1668-1677	excessive	abstract[94]	giv[94]	_	_
15-41	1678-1681	FFA	abstract[94]	giv[94]	_	_
15-42	1682-1684	is	_	_	_	_
15-43	1685-1693	accepted	_	_	_	_
15-44	1694-1698	into	_	_	_	_
15-45	1699-1702	the	object[95]	giv[95]	coref	18-17[121_95]
15-46	1703-1708	liver	object[95]	giv[95]	_	_
15-47	1709-1710	,	_	_	_	_
15-48	1711-1720	gradually	_	_	_	_
15-49	1721-1733	accumulating	_	_	_	_
15-50	1734-1735	.	_	_	_	_

#Text=According to previous studies , palmitic acid and high-fat ( HF ) diet markedly increased CD36 expression , which is closely associated with the development of NAFLD .
16-1	1736-1745	According	_	_	_	_
16-2	1746-1748	to	_	_	_	_
16-3	1749-1757	previous	event[96]	new[96]	coref	17-3[105_96]
16-4	1758-1765	studies	event[96]	new[96]	_	_
16-5	1766-1767	,	_	_	_	_
16-6	1768-1776	palmitic	substance[97]	giv[97]	coref	17-9[0_97]
16-7	1777-1781	acid	substance[97]	giv[97]	_	_
16-8	1782-1785	and	_	_	_	_
16-9	1786-1794	high-fat	object	new	_	_
16-10	1795-1796	(	_	_	_	_
16-11	1797-1799	HF	substance	new	coref	22-7
16-12	1800-1801	)	_	_	_	_
16-13	1802-1806	diet	event	new	coref	22-6[155_0]
16-14	1807-1815	markedly	abstract[102]	new[102]	coref	21-15[140_102]
16-15	1816-1825	increased	abstract[102]	new[102]	_	_
16-16	1826-1830	CD36	person|abstract[102]	new|new[102]	_	_
16-17	1831-1841	expression	abstract[102]	new[102]	_	_
16-18	1842-1843	,	_	_	_	_
16-19	1844-1849	which	_	_	_	_
16-20	1850-1852	is	_	_	_	_
16-21	1853-1860	closely	_	_	_	_
16-22	1861-1871	associated	_	_	_	_
16-23	1872-1876	with	_	_	_	_
16-24	1877-1880	the	event[103]	new[103]	_	_
16-25	1881-1892	development	event[103]	new[103]	_	_
16-26	1893-1895	of	event[103]	new[103]	_	_
16-27	1896-1901	NAFLD	event[103]|abstract	new[103]|giv	coref	20-8
16-28	1902-1903	.	_	_	_	_

#Text=Furthermore , several studies have indicated that fatty acid overflow by activated CD36 subsequently produced a higher level of reactive oxygen species ( ROS ) , which could be linked to oxidative stress .
17-1	1904-1915	Furthermore	_	_	_	_
17-2	1916-1917	,	_	_	_	_
17-3	1918-1925	several	event[105]	giv[105]	_	_
17-4	1926-1933	studies	event[105]	giv[105]	_	_
17-5	1934-1938	have	_	_	_	_
17-6	1939-1948	indicated	_	_	_	_
17-7	1949-1953	that	_	_	_	_
17-8	1954-1959	fatty	abstract[107]	new[107]	_	_
17-9	1960-1964	acid	substance|abstract[107]	giv|new[107]	coref	21-30
17-10	1965-1973	overflow	abstract[107]	new[107]	_	_
17-11	1974-1976	by	abstract[107]	new[107]	_	_
17-12	1977-1986	activated	abstract[107]|abstract[108]	new[107]|giv[108]	_	_
17-13	1987-1991	CD36	abstract[107]|abstract[108]	new[107]|giv[108]	_	_
17-14	1992-2004	subsequently	_	_	_	_
17-15	2005-2013	produced	_	_	_	_
17-16	2014-2015	a	quantity[109]	new[109]	_	_
17-17	2016-2022	higher	quantity[109]	new[109]	_	_
17-18	2023-2028	level	quantity[109]	new[109]	_	_
17-19	2029-2031	of	quantity[109]	new[109]	_	_
17-20	2032-2040	reactive	quantity[109]|abstract[111]	new[109]|new[111]	_	_
17-21	2041-2047	oxygen	quantity[109]|substance|abstract[111]	new[109]|new|new[111]	_	_
17-22	2048-2055	species	quantity[109]|abstract[111]	new[109]|new[111]	_	_
17-23	2056-2057	(	_	_	_	_
17-24	2058-2061	ROS	substance	new	coref	18-10
17-25	2062-2063	)	_	_	_	_
17-26	2064-2065	,	_	_	_	_
17-27	2066-2071	which	_	_	_	_
17-28	2072-2077	could	_	_	_	_
17-29	2078-2080	be	_	_	_	_
17-30	2081-2087	linked	_	_	_	_
17-31	2088-2090	to	_	_	_	_
17-32	2091-2100	oxidative	abstract|abstract[114]	new|new[114]	coref|coref	18-1[115_114]|21-9
17-33	2101-2107	stress	abstract[114]	new[114]	_	_
17-34	2108-2109	.	_	_	_	_

#Text=Oxidative stress is the imbalance between the production of ROS and the activation of antioxidants in the body and results in several metabolic disorders .
18-1	2110-2119	Oxidative	abstract[115]	giv[115]	coref	18-4[116_115]
18-2	2120-2126	stress	abstract[115]	giv[115]	_	_
18-3	2127-2129	is	_	_	_	_
18-4	2130-2133	the	abstract[116]	giv[116]	coref	20-10[134_116]
18-5	2134-2143	imbalance	abstract[116]	giv[116]	_	_
18-6	2144-2151	between	abstract[116]	giv[116]	_	_
18-7	2152-2155	the	abstract[116]|abstract[117]	giv[116]|new[117]	coref	22-31[164_117]
18-8	2156-2166	production	abstract[116]|abstract[117]	giv[116]|new[117]	_	_
18-9	2167-2169	of	abstract[116]|abstract[117]	giv[116]|new[117]	_	_
18-10	2170-2173	ROS	abstract[116]|abstract[117]|substance	giv[116]|new[117]|giv	coref	22-34
18-11	2174-2177	and	abstract[116]	giv[116]	_	_
18-12	2178-2181	the	abstract[116]|abstract[119]	giv[116]|new[119]	ana	19-1[0_119]
18-13	2182-2192	activation	abstract[116]|abstract[119]	giv[116]|new[119]	_	_
18-14	2193-2195	of	abstract[116]|abstract[119]	giv[116]|new[119]	_	_
18-15	2196-2208	antioxidants	abstract[116]|abstract[119]|substance[120]	giv[116]|new[119]|new[120]	coref	26-5[184_120]
18-16	2209-2211	in	abstract[116]|abstract[119]|substance[120]	giv[116]|new[119]|new[120]	_	_
18-17	2212-2215	the	abstract[116]|abstract[119]|substance[120]|object[121]	giv[116]|new[119]|new[120]|giv[121]	coref	23-23[173_121]
18-18	2216-2220	body	abstract[116]|abstract[119]|substance[120]|object[121]	giv[116]|new[119]|new[120]|giv[121]	_	_
18-19	2221-2224	and	abstract[116]|abstract[119]|substance[120]|object[121]	giv[116]|new[119]|new[120]|giv[121]	_	_
18-20	2225-2232	results	abstract[116]|abstract[119]|substance[120]|object[121]|abstract[122]	giv[116]|new[119]|new[120]|giv[121]|new[122]	_	_
18-21	2233-2235	in	abstract[116]|abstract[119]|substance[120]|object[121]|abstract[122]	giv[116]|new[119]|new[120]|giv[121]|new[122]	_	_
18-22	2236-2243	several	abstract[116]|abstract[119]|substance[120]|object[121]|abstract[122]|abstract[124]	giv[116]|new[119]|new[120]|giv[121]|new[122]|new[124]	coref	23-3[167_124]
18-23	2244-2253	metabolic	abstract[116]|abstract[119]|substance[120]|object[121]|abstract[122]|abstract|abstract[124]	giv[116]|new[119]|new[120]|giv[121]|new[122]|new|new[124]	coref	23-3
18-24	2254-2263	disorders	abstract[116]|abstract[119]|substance[120]|object[121]|abstract[122]|abstract[124]	giv[116]|new[119]|new[120]|giv[121]|new[122]|new[124]	_	_
18-25	2264-2265	.	_	_	_	_

#Text=It particularly produces a disturbance in lipid metabolism , eventually leading to lipid accumulation in hepatocytes .
19-1	2266-2268	It	abstract	giv	_	_
19-2	2269-2281	particularly	_	_	_	_
19-3	2282-2290	produces	_	_	_	_
19-4	2291-2292	a	abstract[126]	new[126]	_	_
19-5	2293-2304	disturbance	abstract[126]	new[126]	_	_
19-6	2305-2307	in	abstract[126]	new[126]	_	_
19-7	2308-2313	lipid	abstract[126]|object|abstract[128]	new[126]|giv|giv[128]	coref	19-13
19-8	2314-2324	metabolism	abstract[126]|abstract[128]	new[126]|giv[128]	_	_
19-9	2325-2326	,	_	_	_	_
19-10	2327-2337	eventually	_	_	_	_
19-11	2338-2345	leading	_	_	_	_
19-12	2346-2348	to	_	_	_	_
19-13	2349-2354	lipid	abstract|abstract[130]	giv|giv[130]	coref|coref	28-8|28-8[204_130]
19-14	2355-2367	accumulation	abstract[130]	giv[130]	_	_
19-15	2368-2370	in	abstract[130]	giv[130]	_	_
19-16	2371-2382	hepatocytes	abstract[130]|object	giv[130]|giv	coref	21-12
19-17	2383-2384	.	_	_	_	_

#Text=Of the several existing pathogenic mechanisms of NAFLD , oxidative stress is considered a major contributor .
20-1	2385-2387	Of	_	_	_	_
20-2	2388-2391	the	abstract[132]	new[132]	_	_
20-3	2392-2399	several	abstract[132]	new[132]	_	_
20-4	2400-2408	existing	abstract[132]	new[132]	_	_
20-5	2409-2419	pathogenic	abstract[132]	new[132]	_	_
20-6	2420-2430	mechanisms	abstract[132]	new[132]	_	_
20-7	2431-2433	of	abstract[132]	new[132]	_	_
20-8	2434-2439	NAFLD	abstract[132]|substance	new[132]|giv	_	_
20-9	2440-2441	,	_	_	_	_
20-10	2442-2451	oxidative	abstract[134]	giv[134]	coref	21-7[138_134]
20-11	2452-2458	stress	abstract[134]	giv[134]	_	_
20-12	2459-2461	is	_	_	_	_
20-13	2462-2472	considered	_	_	_	_
20-14	2473-2474	a	abstract[135]	new[135]	_	_
20-15	2475-2480	major	abstract[135]	new[135]	_	_
20-16	2481-2492	contributor	abstract[135]	new[135]	_	_
20-17	2493-2494	.	_	_	_	_

#Text=According to a previous study , uric acid-induced oxidative stress in hepatocytes significantly elevated the expression of lipogenesis factors such as acetyl-coenzyme A carboxylase ( ACC ) , fatty acid synthase ( FAS ) , and sterol regulatory element-binding protein-1c ( SREBP-1c ) .
21-1	2495-2504	According	_	_	_	_
21-2	2505-2507	to	_	_	_	_
21-3	2508-2509	a	abstract[136]	new[136]	coref	22-1[153_136]
21-4	2510-2518	previous	abstract[136]	new[136]	_	_
21-5	2519-2524	study	abstract[136]	new[136]	_	_
21-6	2525-2526	,	_	_	_	_
21-7	2527-2531	uric	abstract[138]	giv[138]	coref	23-7[168_138]
21-8	2532-2544	acid-induced	abstract[138]	giv[138]	_	_
21-9	2545-2554	oxidative	abstract|abstract[138]	giv|giv[138]	coref	28-11
21-10	2555-2561	stress	abstract[138]	giv[138]	_	_
21-11	2562-2564	in	abstract[138]	giv[138]	_	_
21-12	2565-2576	hepatocytes	abstract[138]|place	giv[138]|giv	_	_
21-13	2577-2590	significantly	_	_	_	_
21-14	2591-2599	elevated	_	_	_	_
21-15	2600-2603	the	abstract[140]	giv[140]	_	_
21-16	2604-2614	expression	abstract[140]	giv[140]	_	_
21-17	2615-2617	of	abstract[140]	giv[140]	_	_
21-18	2618-2629	lipogenesis	abstract[140]|abstract|abstract[142]	giv[140]|new|giv[142]	_	_
21-19	2630-2637	factors	abstract[140]|abstract[142]	giv[140]|giv[142]	_	_
21-20	2638-2642	such	abstract[140]	giv[140]	_	_
21-21	2643-2645	as	abstract[140]	giv[140]	_	_
21-22	2646-2661	acetyl-coenzyme	abstract[140]|abstract	giv[140]|new	appos	21-23[144_0]
21-23	2662-2663	A	object[144]	giv[144]	appos	21-26[0_144]
21-24	2664-2675	carboxylase	object[144]	giv[144]	_	_
21-25	2676-2677	(	_	_	_	_
21-26	2678-2681	ACC	object	giv	_	_
21-27	2682-2683	)	_	_	_	_
21-28	2684-2685	,	_	_	_	_
21-29	2686-2691	fatty	abstract[147]	new[147]	appos	21-33[0_147]
21-30	2692-2696	acid	substance|abstract[147]	giv|new[147]	_	_
21-31	2697-2705	synthase	abstract[147]	new[147]	_	_
21-32	2706-2707	(	_	_	_	_
21-33	2708-2711	FAS	abstract	giv	_	_
21-34	2712-2713	)	_	_	_	_
21-35	2714-2715	,	_	_	_	_
21-36	2716-2719	and	_	_	_	_
21-37	2720-2726	sterol	abstract|abstract[151]	new|new[151]	_	_
21-38	2727-2737	regulatory	abstract[151]	new[151]	_	_
21-39	2738-2753	element-binding	abstract|abstract[151]	new|new[151]	_	_
21-40	2754-2764	protein-1c	abstract[151]	new[151]	_	_
21-41	2765-2766	(	_	_	_	_
21-42	2767-2775	SREBP-1c	abstract	new	_	_
21-43	2776-2777	)	_	_	_	_
21-44	2778-2779	.	_	_	_	_

#Text=Another study has shown that an HF diet destroyed the antioxidant defense system by decreasing superoxide dismutase ( SOD ) and catalase ( CAT ) activities , and markedly increased the production of ROS .
22-1	2780-2787	Another	abstract[153]	giv[153]	coref	27-4[193_153]
22-2	2788-2793	study	abstract[153]	giv[153]	_	_
22-3	2794-2797	has	_	_	_	_
22-4	2798-2803	shown	_	_	_	_
22-5	2804-2808	that	_	_	_	_
22-6	2809-2811	an	event[155]	giv[155]	_	_
22-7	2812-2814	HF	animal|event[155]	giv|giv[155]	_	_
22-8	2815-2819	diet	event[155]	giv[155]	_	_
22-9	2820-2829	destroyed	_	_	_	_
22-10	2830-2833	the	abstract[157]	new[157]	_	_
22-11	2834-2845	antioxidant	abstract[157]	new[157]	_	_
22-12	2846-2853	defense	abstract|abstract[157]	new|new[157]	_	_
22-13	2854-2860	system	abstract[157]	new[157]	_	_
22-14	2861-2863	by	_	_	_	_
22-15	2864-2874	decreasing	_	_	_	_
22-16	2875-2885	superoxide	substance|abstract[159]	new|new[159]	_	_
22-17	2886-2895	dismutase	abstract[159]	new[159]	_	_
22-18	2896-2897	(	_	_	_	_
22-19	2898-2901	SOD	substance	new	_	_
22-20	2902-2903	)	_	_	_	_
22-21	2904-2907	and	_	_	_	_
22-22	2908-2916	catalase	object	new	appos	22-24
22-23	2917-2918	(	_	_	_	_
22-24	2919-2922	CAT	object	giv	_	_
22-25	2923-2924	)	_	_	_	_
22-26	2925-2935	activities	abstract	new	_	_
22-27	2936-2937	,	_	_	_	_
22-28	2938-2941	and	_	_	_	_
22-29	2942-2950	markedly	_	_	_	_
22-30	2951-2960	increased	_	_	_	_
22-31	2961-2964	the	abstract[164]	giv[164]	coref	23-16[171_164]
22-32	2965-2975	production	abstract[164]	giv[164]	_	_
22-33	2976-2978	of	abstract[164]	giv[164]	_	_
22-34	2979-2982	ROS	abstract[164]|substance	giv[164]|giv	coref	23-16
22-35	2983-2984	.	_	_	_	_

#Text=To prevent metabolic disorders due to oxidative stress , antioxidative capability that suppresses or eliminates ROS production plays an important role in the body .
23-1	2985-2987	To	_	_	_	_
23-2	2988-2995	prevent	_	_	_	_
23-3	2996-3005	metabolic	abstract|abstract[167]	giv|giv[167]	_	_
23-4	3006-3015	disorders	abstract[167]	giv[167]	_	_
23-5	3016-3019	due	abstract[167]	giv[167]	_	_
23-6	3020-3022	to	_	_	_	_
23-7	3023-3032	oxidative	abstract[168]	giv[168]	coref	28-11[206_168]
23-8	3033-3039	stress	abstract[168]	giv[168]	_	_
23-9	3040-3041	,	_	_	_	_
23-10	3042-3055	antioxidative	abstract[169]	new[169]	_	_
23-11	3056-3066	capability	abstract[169]	new[169]	_	_
23-12	3067-3071	that	_	_	_	_
23-13	3072-3082	suppresses	_	_	_	_
23-14	3083-3085	or	_	_	_	_
23-15	3086-3096	eliminates	_	_	_	_
23-16	3097-3100	ROS	substance|abstract[171]	giv|giv[171]	coref	24-14
23-17	3101-3111	production	abstract[171]	giv[171]	_	_
23-18	3112-3117	plays	_	_	_	_
23-19	3118-3120	an	abstract[172]	new[172]	_	_
23-20	3121-3130	important	abstract[172]	new[172]	_	_
23-21	3131-3135	role	abstract[172]	new[172]	_	_
23-22	3136-3138	in	abstract[172]	new[172]	_	_
23-23	3139-3142	the	abstract[172]|object[173]	new[172]|giv[173]	coref	26-27[0_173]
23-24	3143-3147	body	abstract[172]|object[173]	new[172]|giv[173]	_	_
23-25	3148-3149	.	_	_	_	_

#Text=Plants contain a variety of phytochemicals that have antioxidant ability to effectively remove ROS .
24-1	3150-3156	Plants	plant	new	_	_
24-2	3157-3164	contain	_	_	_	_
24-3	3165-3166	a	abstract[175]	new[175]	_	_
24-4	3167-3174	variety	abstract[175]	new[175]	_	_
24-5	3175-3177	of	abstract[175]	new[175]	_	_
24-6	3178-3192	phytochemicals	abstract[175]|substance	new[175]|new	_	_
24-7	3193-3197	that	_	_	_	_
24-8	3198-3202	have	_	_	_	_
24-9	3203-3214	antioxidant	person|abstract[178]	new|new[178]	_	_
24-10	3215-3222	ability	abstract[178]	new[178]	_	_
24-11	3223-3225	to	_	_	_	_
24-12	3226-3237	effectively	_	_	_	_
24-13	3238-3244	remove	_	_	_	_
24-14	3245-3248	ROS	substance	giv	_	_
24-15	3249-3250	.	_	_	_	_

#Text=Curcuma longa L. is a flowering plant of the ginger family ( Zingiberaceae ) .
25-1	3251-3258	Curcuma	_	_	_	_
25-2	3259-3264	longa	_	_	_	_
25-3	3265-3267	L.	_	_	_	_
25-4	3268-3270	is	_	_	_	_
25-5	3271-3272	a	plant[180]	new[180]	_	_
25-6	3273-3282	flowering	plant[180]	new[180]	_	_
25-7	3283-3288	plant	plant[180]	new[180]	_	_
25-8	3289-3291	of	plant[180]	new[180]	_	_
25-9	3292-3295	the	plant[180]|person[181]	new[180]|new[181]	_	_
25-10	3296-3302	ginger	plant[180]|person[181]	new[180]|new[181]	_	_
25-11	3303-3309	family	plant[180]|person[181]	new[180]|new[181]	_	_
25-12	3310-3311	(	_	_	_	_
25-13	3312-3325	Zingiberaceae	plant	new	_	_
25-14	3326-3327	)	_	_	_	_
25-15	3328-3329	.	_	_	_	_

#Text=As C. longa possesses natural antioxidants , which leads to free radical scavenging potential , it has been widely used to prevent many diseases , including liver injury .
26-1	3330-3332	As	_	_	_	_
26-2	3333-3335	C.	person	new	coref	27-24
26-3	3336-3341	longa	_	_	_	_
26-4	3342-3351	possesses	_	_	_	_
26-5	3352-3359	natural	substance[184]	giv[184]	_	_
26-6	3360-3372	antioxidants	substance[184]	giv[184]	_	_
26-7	3373-3374	,	_	_	_	_
26-8	3375-3380	which	_	_	_	_
26-9	3381-3386	leads	_	_	_	_
26-10	3387-3389	to	_	_	_	_
26-11	3390-3394	free	abstract[186]	new[186]	ana	26-16[0_186]
26-12	3395-3402	radical	abstract[186]	new[186]	_	_
26-13	3403-3413	scavenging	abstract|abstract[186]	new|new[186]	_	_
26-14	3414-3423	potential	abstract[186]	new[186]	_	_
26-15	3424-3425	,	_	_	_	_
26-16	3426-3428	it	abstract	giv	_	_
26-17	3429-3432	has	_	_	_	_
26-18	3433-3437	been	_	_	_	_
26-19	3438-3444	widely	_	_	_	_
26-20	3445-3449	used	_	_	_	_
26-21	3450-3452	to	_	_	_	_
26-22	3453-3460	prevent	_	_	_	_
26-23	3461-3465	many	abstract[188]	giv[188]	_	_
26-24	3466-3474	diseases	abstract[188]	giv[188]	_	_
26-25	3475-3476	,	abstract[188]	giv[188]	_	_
26-26	3477-3486	including	abstract[188]	giv[188]	_	_
26-27	3487-3492	liver	abstract[188]|object|event[190]	giv[188]|giv|new[190]	coref	27-30[200_0]
26-28	3493-3499	injury	abstract[188]|event[190]	giv[188]|new[190]	_	_
26-29	3500-3501	.	_	_	_	_

#Text=The aim of our study was to investigate in vitro and in vivo protective effects of hot water extract ( CLW ) from C. longa on the development of fatty liver .
27-1	3502-3505	The	abstract[191]	new[191]	_	_
27-2	3506-3509	aim	abstract[191]	new[191]	_	_
27-3	3510-3512	of	abstract[191]	new[191]	_	_
27-4	3513-3516	our	abstract[191]|person|abstract[193]	new[191]|acc|giv[193]	_	_
27-5	3517-3522	study	abstract[191]|abstract[193]	new[191]|giv[193]	_	_
27-6	3523-3526	was	_	_	_	_
27-7	3527-3529	to	_	_	_	_
27-8	3530-3541	investigate	_	_	_	_
27-9	3542-3544	in	_	_	_	_
27-10	3545-3550	vitro	_	_	_	_
27-11	3551-3554	and	_	_	_	_
27-12	3555-3557	in	_	_	_	_
27-13	3558-3562	vivo	abstract[194]	new[194]	_	_
27-14	3563-3573	protective	abstract[194]	new[194]	_	_
27-15	3574-3581	effects	abstract[194]	new[194]	_	_
27-16	3582-3584	of	abstract[194]	new[194]	_	_
27-17	3585-3588	hot	abstract[194]|substance[196]	new[194]|new[196]	appos	27-21[0_196]
27-18	3589-3594	water	abstract[194]|substance|substance[196]	new[194]|new|new[196]	_	_
27-19	3595-3602	extract	abstract[194]|substance[196]	new[194]|new[196]	_	_
27-20	3603-3604	(	_	_	_	_
27-21	3605-3608	CLW	substance	giv	_	_
27-22	3609-3610	)	_	_	_	_
27-23	3611-3615	from	_	_	_	_
27-24	3616-3618	C.	person	giv	_	_
27-25	3619-3624	longa	_	_	_	_
27-26	3625-3627	on	_	_	_	_
27-27	3628-3631	the	abstract[199]	new[199]	_	_
27-28	3632-3643	development	abstract[199]	new[199]	_	_
27-29	3644-3646	of	abstract[199]	new[199]	_	_
27-30	3647-3652	fatty	abstract[199]|object[200]	new[199]|giv[200]	coref	28-15[0_200]
27-31	3653-3658	liver	abstract[199]|object[200]	new[199]|giv[200]	_	_
27-32	3659-3660	.	_	_	_	_

#Text=Furthermore , the mode of action against lipid accumulation and oxidative stress in non-alcoholic liver damage was determined .
28-1	3661-3672	Furthermore	_	_	_	_
28-2	3673-3674	,	_	_	_	_
28-3	3675-3678	the	abstract[201]	new[201]	_	_
28-4	3679-3683	mode	abstract[201]	new[201]	_	_
28-5	3684-3686	of	abstract[201]	new[201]	_	_
28-6	3687-3693	action	abstract[201]|abstract[202]	new[201]|new[202]	_	_
28-7	3694-3701	against	abstract[201]|abstract[202]	new[201]|new[202]	_	_
28-8	3702-3707	lipid	abstract[201]|abstract[202]|abstract|abstract[204]	new[201]|new[202]|giv|giv[204]	_	_
28-9	3708-3720	accumulation	abstract[201]|abstract[202]|abstract[204]	new[201]|new[202]|giv[204]	_	_
28-10	3721-3724	and	abstract[201]|abstract[202]	new[201]|new[202]	_	_
28-11	3725-3734	oxidative	abstract[201]|abstract[202]|abstract|abstract[206]	new[201]|new[202]|giv|giv[206]	_	_
28-12	3735-3741	stress	abstract[201]|abstract[202]|abstract[206]	new[201]|new[202]|giv[206]	_	_
28-13	3742-3744	in	abstract[201]	new[201]	_	_
28-14	3745-3758	non-alcoholic	abstract[201]|abstract[208]	new[201]|new[208]	_	_
28-15	3759-3764	liver	abstract[201]|object|abstract[208]	new[201]|giv|new[208]	_	_
28-16	3765-3771	damage	abstract[201]|abstract[208]	new[201]|new[208]	_	_
28-17	3772-3775	was	_	_	_	_
28-18	3776-3786	determined	_	_	_	_
28-19	3787-3788	.	_	_	_	_
